Bebtelovimab FDA Approval Status
FDA Approved: No
Generic name: bebtelovimab
Dosage form: Injection
Company: Eli Lilly and Company
Treatment for: COVID-19
Bebtelovimab is an investigational human immunoglobulin G-1 (IgG1 variant) monoclonal antibody (mAb) directed against the spike protein of SARS-CoV-2 for the treatment of COVID-19.
- On February 11, 2022, the U.S. Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for bebtelovimab for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients who are at high risk for progression to severe COVID-19. Bebtelovimab demonstrated binding and neutralizing activity across the variants of concern at that time, including Omicron and BA.2.
- On November 30, 2022, the FDA announced the withdrawal of the Emergency Use Authorization for bebtelovimab for the treatment of COVID-19 because it is not expected to neutralize the Omicron subvariants BQ.1 and BQ.1.1.
Development timeline for bebtelovimab
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
